Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10363941" target="_blank" >RIV/00216208:11110/17:10363941 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00843989:_____/17:E0105911 RIV/00064190:_____/17:N0000062 RIV/00064165:_____/17:10363941

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.ejogrb.2016.12.030" target="_blank" >http://dx.doi.org/10.1016/j.ejogrb.2016.12.030</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ejogrb.2016.12.030" target="_blank" >10.1016/j.ejogrb.2016.12.030</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study

Popis výsledku v původním jazyce

Objective: The objective of this project was to evaluate treatment persistence in patients being treated for overactive bladder syndrome (OAB) with mirabegron, employing clinical follow-up in a prospective, multicenter study. Study design: This is an analysis of patients who started treatment with mirabegron between May and September 2014 and were evaluated 1 year after treatment commenced. During this evaluation we determined how many patients stopped treatment and established their reasons for discontinuation. Results: 206 patients being treated for OAB with mirabegron were evaluated a year after starting treatment. It emerged that 60 patients (29.1%) had discontinued the treatment, citing the following reasons: 24/60 insufficient treatment efficacy, 26/60 other reasons, while 10 members of the group discontinued treatment because of side effects. 75 out of 206 patients were &lt;= 60 years old and 28% terminated the study prematurely: 131 out of 206 were &gt; 60 years old and 29.2% terminated the study prematurely. In the group of patients without previous OAB treatment 35.7% discontinued treatment with mirabegron, while 28.1% of patients with previous anticholinergic treatment discontinued treatment. Conclusion: In our clinical prospective multicenter study, persistence in treatment with mirabegron reached a figure of 71%.

Název v anglickém jazyce

Persistence in the treatment of overactive bladder syndrome (OAB) with mirabegron in a multicenter clinical study

Popis výsledku anglicky

Objective: The objective of this project was to evaluate treatment persistence in patients being treated for overactive bladder syndrome (OAB) with mirabegron, employing clinical follow-up in a prospective, multicenter study. Study design: This is an analysis of patients who started treatment with mirabegron between May and September 2014 and were evaluated 1 year after treatment commenced. During this evaluation we determined how many patients stopped treatment and established their reasons for discontinuation. Results: 206 patients being treated for OAB with mirabegron were evaluated a year after starting treatment. It emerged that 60 patients (29.1%) had discontinued the treatment, citing the following reasons: 24/60 insufficient treatment efficacy, 26/60 other reasons, while 10 members of the group discontinued treatment because of side effects. 75 out of 206 patients were &lt;= 60 years old and 28% terminated the study prematurely: 131 out of 206 were &gt; 60 years old and 29.2% terminated the study prematurely. In the group of patients without previous OAB treatment 35.7% discontinued treatment with mirabegron, while 28.1% of patients with previous anticholinergic treatment discontinued treatment. Conclusion: In our clinical prospective multicenter study, persistence in treatment with mirabegron reached a figure of 71%.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30214 - Obstetrics and gynaecology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Obstetrics &amp; Gynecology and Reproductive Biology

ISSN

0301-2115

e-ISSN

—

Svazek periodika

210

Číslo periodika v rámci svazku

March

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

4

Strana od-do

247-250

Kód UT WoS článku

000401878500040

EID výsledku v databázi Scopus

2-s2.0-85008653890